Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903914 · ClinicalTrials.gov registry record · Phase 1
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
NCT02903914 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 260 participants.
The verdict
NCT02903914, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
Study Summary
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG INCB001158
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2016-09-14 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903914
The ClinicalTrials.gov registry entry for NCT02903914 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02903914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02903914 about?
NCT02903914 is a clinical study titled "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors". This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
What is the current status of trial NCT02903914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2016-09-14. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT02903914?
The interventions under investigation include: Pembrolizumab (DRUG), INCB001158 (DRUG).
Who is sponsoring clinical trial NCT02903914?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.